Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy

被引:75
|
作者
Ashrafizadeh, Milad [1 ,2 ]
Zarrabi, Ali [2 ]
Hushmandi, Kiavash [3 ]
Hashemi, Farid [4 ]
Moghadam, Ebrahim Rahmani [5 ]
Raei, Mehdi [6 ]
Kalantari, Mahshad [7 ]
Tavakol, Shima [8 ]
Mohammadinejad, Reza [9 ]
Najafi, Masoud [11 ,12 ]
Tay, Franklin R. [10 ]
Makvandi, Pooyan [13 ,14 ]
机构
[1] Sabanci Univ, Fac Engn & Nat Sci, TR-34956 Istanbul, Turkey
[2] Sabanci Univ Nanotechnol Res & Applicat Ctr SUNUM, TR-34956 Istanbul, Turkey
[3] Univ Tehran, Fac Vet Med, Dept Food Hyg & Qual Control, Div Epidemiol & Zoonoses, Tehran 1419963114, Iran
[4] Univ Tehran, Fac Vet Med, Dept Comparat Biosci, Tehran, Iran
[5] Shiraz Univ Med Sci, Sch Med, Dept Anat Sci, Student Res Comm, Shiraz 7134814336, Iran
[6] Baqiyatallah Univ Med Sci, Hlth Res Ctr, Life Style Inst, Tehran 1435916471, Iran
[7] Azad Univ, Dept Genet, Tehran Med Sci Branch, Tehran 19168931813, Iran
[8] Iran Univ Med Sci, Cellular & Mol Res Ctr, Tehran 1449614525, Iran
[9] Kerman Univ Med Sci, Pharmaceut Res Ctr, Inst Neuropharmacol, Kerman 7616911319, Iran
[10] Augusta Univ, Coll Grad Studies, Augusta, GA 30912 USA
[11] Kermanshah Univ Med Sci, Med Technol Res Ctr, Inst Hlth Technol, Sch Paramed Sci, Kermanshah 6715847141, Iran
[12] Kermanshah Univ Med Sci, Sch Paramed Sci, Radiol & Nucl Med Dept, Kermanshah 6715847141, Iran
[13] Ist Italiano Tecnol, Ctr MicroBioRobot, I-56025 Pisa, Italy
[14] Iran Univ Med Sci, Fac Adv Technol Med, Dept Med Nanotechnol, Tehran 1449614535, Iran
关键词
anticancer therapy; chemotherapy; co-delivery platforms; nanocarriers; natural products; small interfering RNA; LOW-DENSITY-LIPOPROTEIN; MESOPOROUS SILICA NANOPARTICLES; CHITOSAN-BASED NANOPARTICLES; EPITHELIAL-MESENCHYMAL TRANSITION; ENHANCED ANTICANCER EFFICACY; MODIFIED CATIONIC LIPOSOMES; SOLID LIPID NANOPARTICLES; CELL-CYCLE REDISTRIBUTION; ANTI-SURVIVIN SIRNA; NANO-GRAPHENE OXIDE;
D O I
10.1021/acscombsci.0c00099
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
Chemotherapy using natural compounds, such as resveratrol, curcumin, paclitaxel, docetaxel, etoposide, doxorubicin, and camptothecin, is of importance in cancer therapy because of the outstanding therapeutic activity and multitargeting capability of these compounds. However, poor solubility and bioavailability of natural compounds have limited their efficacy in cancer therapy. To circumvent this hurdle, nanocarriers have been designed to improve the antitumor activity of the aforementioned compounds. Nevertheless, cancer treatment is still a challenge, demanding novel strategies. It is well-known that a combination of natural products and gene therapy is advantageous over monotherapy. Delivery of multiple therapeutic agents/small interfering RNA (siRNA) as a potent gene-editing tool in cancer therapy can maximize the synergistic effects against tumor cells. In the present review, codelivery of natural compounds/siRNA using nanovehicles are highlighted to provide a backdrop for future research.
引用
收藏
页码:669 / 700
页数:32
相关论文
共 50 条
  • [41] Smart Drug and Gene Co-Delivery System for Cancer Therapy
    Zhou, Shuai
    Chen, Wei
    Xiao, Zilin
    Ye, Sheng
    Ding, Chendi
    Fu, Jiajun
    PROGRESS IN CHEMISTRY, 2017, 29 (05) : 502 - 512
  • [42] Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy
    Mirzaei, Sepideh
    Gholami, Mohammad Hossein
    Ang, Hui Li
    Hashemi, Farid
    Zarrabi, Ali
    Zabolian, Amirhossein
    Hushmandi, Kiavash
    Delfi, Masoud
    Khan, Haroon
    Ashrafizadeh, Milad
    Sethi, Gautam
    Kumar, Alan Prem
    CELLS, 2021, 10 (12)
  • [43] Co-delivery Strategies Based on Multifunctional Nanocarriers for Cancer Therapy
    Chen, Hao
    Zhao, Ying
    Wang, Hai
    Nie, Guangjun
    Nan, Kaihui
    CURRENT DRUG METABOLISM, 2012, 13 (08) : 1087 - 1096
  • [44] Curcumin delivery and co-delivery based on nanomaterials as an effective approach for cancer therapy
    Pourmadadi, Mehrab
    Abbasi, Parisa
    Eshaghi, Mohammad Mahdi
    Bakhshi, Ali
    Manicum, Amanda-Lee Ezra
    Rahdar, Abbas
    Pandey, Sadanand
    Jadoun, Sapana
    Diez-Pascual, Ana M.
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2022, 78
  • [45] Targeted combination therapy for glioblastoma by co-delivery of doxorubicin, YAP-siRNA and gold nanorods
    Li, Lihuang
    Guo, Qiuyan
    Liu, Yanxiu
    Lu, Mindan
    Yang, Jun
    Ge, Yunlong
    Zhang, Qiang
    Sun, Benqiang
    Wang, Xiumin
    Liang-cheng, Li
    Ren, Lei
    JOURNAL OF MATERIALS SCIENCE & TECHNOLOGY, 2021, 63 : 81 - 90
  • [46] Targeted combination therapy for glioblastoma by co-delivery of doxorubicin, YAP-siRNA and gold nanorods
    Lihuang Li
    Qiuyan Guo
    Yanxiu Liu
    Mindan Lu
    Jun Yang
    Yunlong Ge
    Qiang Zhang
    Benqiang Sun
    Xiumin Wang
    Li Liang-cheng
    Lei Ren
    Journal of Materials Science & Technology, 2021, 63 (04) : 81 - 90
  • [47] Targeted combination therapy for glioblastoma by co-delivery of doxorubicin, YAP-siRNA and gold nanorods
    Lihuang, Li
    Qiuyan, Guo
    Yanxiu, Liu
    Mindan, Lu
    Jun, Yang
    Yunlong, Ge
    Qiang, Zhang
    Benqiang, Sun
    Xiumin, Wang
    Liang-cheng, Li
    Lei, Ren
    Journal of Materials Science and Technology, 2021, 63 : 81 - 90
  • [48] Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA
    Ball, Rebecca L.
    Hajj, Khalid A.
    Vizelman, Jamie
    Bajaj, Palak
    Whitehead, Kathryn A.
    NANO LETTERS, 2018, 18 (06) : 3814 - 3822
  • [49] Intracellular Co-delivery of native antibody and siRNA for combination therapy by using biodegradable silica nanocapsules
    Yuan, Peiyan
    Yang, Fen
    Liew, Si Si
    Yan, Jiachang
    Dong, Xiao
    Wang, Jinfeng
    Du, Shubo
    Mao, Xin
    Gao, Liqian
    Yao, Shao Q.
    BIOMATERIALS, 2022, 281
  • [50] Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA
    Yu, Yong Hee
    Kim, Eunjoong
    Park, Dai Eui
    Shim, Gayong
    Lee, Sangbin
    Kim, Young Bong
    Kim, Chan-Wha
    Oh, Yu-Kyoung
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2012, 80 (02) : 268 - 273